The company intends to develop pharmaceutical products that use a botanical tobacco component for the treatment of smokeless tobacco dependence, as well as products that would utilize certain monoamine oxidase (MAO) agents in tobacco to treat a range of neurological conditions, including Alzheimer’s disease, Parkinson’s disease, schizophrenia and depression.
Star Scientific’s recently incorporated subsidiary in Delaware will be the vehicle for the company’s pursuit of a range of tobacco-based pharmaceutical products.
A search for a clinical/medical director who would oversee future clinical trials and the development of tobacco-related pharmaceutical products is currently underway.